CYTK NASDAQ
Cytokinetics, Incorporated
1W: -0.7%
1M: +17.8%
3M: +14.9%
YTD: +26.4%
1Y: +139.0%
3Y: +109.7%
5Y: +201.0%
$76.94
-1.12 (-1.43%)
Weekly Expected Move ±10.8%
$60
$68
$76
$84
$92
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
🏦 Institutional Activity
Latest: Q1 2026505
Institutions Holding
+15 vs prior
81.3%
Ownership
+2.55%
73
New
158
Increased
221
Reduced
104
Closed
👔 Insider Trades
25 records| Date | Name | Title | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-05-19 | Malik Fady Ibraham | officer: evp research & development | S-Sale | 3,500 | $75.69 | $265K | Filing |
| 2026-05-05 | Malik Fady Ibraham | officer: evp research & development | S-Sale | 3,500 | $77.37 | $271K | Filing |
| 2026-04-21 | Malik Fady Ibraham | officer: evp research & development | S-Sale | 3,500 | $65.69 | $230K | Filing |
| 2026-04-15 | Daly James M | director | A-Grant/Award | 191 | $65.37 | $12K | Filing |
| 2026-04-15 | Harrington Robert Arthur | director | A-Grant/Award | 191 | $65.37 | $12K | Filing |
| 2026-04-15 | HENDERSON JOHN T | director | A-Grant/Award | 325 | $65.37 | $21K | Filing |
| 2026-04-15 | Kaye Edward M. MD | director | A-Grant/Award | 191 | $65.37 | $12K | Filing |
| 2026-04-15 | WIERENGA WENDELL | director | A-Grant/Award | 95 | $65.37 | $6K | Filing |
| 2026-04-15 | Wysenski Nancy | director | A-Grant/Award | 95 | $65.37 | $6K | Filing |
| 2026-04-15 | Blum Robert I | officer: president & ceo | S-Sale | 7,500 | $65.38 | $490K | Filing |
| 2026-04-15 | Callos Andrew | officer: evp, chief commercial officer | S-Sale | 7,449 | $66.02 | $492K | Filing |
| 2026-04-07 | Malik Fady Ibraham | officer: evp research & development | S-Sale | 3,500 | $65.21 | $228K | Filing |
| 2026-04-07 | Malik Fady Ibraham | officer: evp research & development | S-Sale | 1,000 | $64.75 | $65K | Filing |
| 2026-03-31 | Callos Andrew | officer: evp, chief commercial officer | S-Sale | 3,639 | $65.00 | $237K | Filing |
| 2026-03-17 | Callos Andrew | officer: evp, chief commercial officer | S-Sale | 2,916 | $62.15 | $181K | Filing |
| 2026-03-17 | Callos Andrew | officer: evp, chief commercial officer | S-Sale | 5,626 | $62.15 | $350K | Filing |
| 2026-03-17 | Lee Sung | officer: evp, chief financial officer | S-Sale | 4,935 | $62.15 | $307K | Filing |
| 2026-03-17 | Malik Fady Ibraham | officer: evp research & development | S-Sale | 4,397 | $62.15 | $273K | Filing |
| 2026-03-17 | Malik Fady Ibraham | officer: evp research & development | S-Sale | 7,636 | $62.15 | $475K | Filing |
| 2026-03-16 | Callos Andrew | officer: evp, chief commercial officer | S-Sale | 1,709 | $61.03 | $104K | Filing |
| 2026-03-15 | Blum Robert I | officer: president & ceo | A-Grant/Award | 75,258 | $— | $0 | Filing |
| 2026-03-05 | Callos Andrew | officer: evp, chief commercial officer | S-Sale | 11,000 | $61.88 | $681K | Filing |
| 2026-03-05 | Callos Andrew | officer: evp, chief commercial officer | S-Sale | 15,000 | $61.87 | $928K | Filing |
| 2026-03-02 | PARSHALL B LYNNE | director | S-Sale | 5,000 | $61.21 | $306K | Filing |
| 2026-03-02 | Callos Andrew | officer: evp, chief commercial officer | S-Sale | 886 | $61.62 | $55K | Filing |
🏛️ Congressional Trades
2 records| Date | Politician | Chamber | Type | Amount | Filing |
|---|---|---|---|---|---|
| 2025-06-17 | Lisa McClain | House | Sell | $1,001 - $15,000 | Filing |
| 2025-06-11 | Lisa McClain | House | Buy | $1,001 - $15,000 | Filing |
🏦 Top Institutional Holders
20 holders| Holder | Shares | Value | Date Reported | Filing | |
|---|---|---|---|---|---|
| BlackRock, Inc. | 16,548,011 | $1.1B | +152,888 | 2026-03-31 | Filing |
| FMR LLC | 10,723,140 | $707M | -2,084,612 | 2026-03-31 | Filing |
| WELLINGTON MANAGEMENT GROUP LLP | 8,009,489 | $528M | +72,426 | 2026-03-31 | Filing |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5,843,782 | $385M | +5,843,782 | 2026-03-31 | Filing |
| STATE STREET CORP | 5,745,193 | $379M | -80,102 | 2026-03-31 | Filing |
| VANGUARD CAPITAL MANAGEMENT LLC | 5,488,634 | $362M | +5,488,634 | 2026-03-31 | Filing |
| Avoro Capital Advisors LLC | 3,333,333 | $220M | +3,333,333 | 2026-03-31 | Filing |
| GEODE CAPITAL MANAGEMENT, LLC | 3,215,415 | $212M | +159,398 | 2026-03-31 | Filing |
| BANK OF AMERICA CORP /DE | 3,125,436 | $206M | +184,284 | 2026-03-31 | Filing |
| RTW INVESTMENTS, LP | 2,721,158 | $179M | — | 2026-03-31 | Filing |
| GOLDMAN SACHS GROUP INC | 2,205,758 | $145M | -165,921 | 2026-03-31 | Filing |
| UBS Group AG | 2,077,277 | $137M | +945,821 | 2026-03-31 | Filing |
| Polar Capital Holdings Plc | 1,661,248 | $109M | -761,364 | 2026-03-31 | Filing |
| Integral Health Asset Management, LLC | 1,600,000 | $105M | +200,000 | 2026-03-31 | Filing |
| Paradigm Biocapital Advisors LP | 1,480,857 | $98M | +1,480,857 | 2026-03-31 | Filing |
| NORTHERN TRUST CORP | 1,441,634 | $95M | +60,847 | 2026-03-31 | Filing |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,397,045 | $92M | +13,608 | 2026-03-31 | Filing |
| Deep Track Capital, LP | 1,374,320 | $91M | -1,962,678 | 2026-03-31 | Filing |
| Capital International Investors | 1,338,803 | $88M | +160,023 | 2026-03-31 | Filing |
| Frazier Life Sciences Management, L.P. | 1,159,879 | $76M | +225,237 | 2026-03-31 | Filing |